Purpose Health related quality of life (HRQoL) was characterized among patients with neuroendocrine tumor (NET) and compared with the general Norwegian population. Methods A cross sectional, comparative design was chosen, and the samples comprised 196 NET patients and 5,258 individuals from the general Norwegian population. We used Chi-square cross tab calculations to evaluate sociodemographic characteristics, T-tests for independent samples and Analysis of Variance (ANOVA) in order to compare HRQoL (SF-36) scores across a range of background variables. Furthermore, T-tests were used to analyze differences in HRQoL scores between the samples. Results NET patients demonstrated significantly lower on all HRQoL subscales when compared with the general population with the lowest values on general health, physical limitation and vitality. Individuals above 70 years reported lower scores on physical functioning and physical limitations compared with those who were younger. Individuals with higher levels of education reported increased physical functioning compared with those with less education and full-time or part-time workers described higher physical functioning and less physical limitations compared with those who were retired. Conclusions All SF-36 HRQoL scores were significantly lower among the NET patients when compared with the general population. Assistance from health personnel to NET patients should focus on those domains.
Introduction
Neuroendocrine tumors (NET) or carcinoids are slow growing, rare types of cancer. NET most commonly arise from the gastrointestinal (GI) tract and tend to metastasize. The incidence of NET is estimated to be less than one per 100,000 individuals [1] the most common GI tract carcinoids are gastric, small intestinal, appendiceal, colonic and rectal. The hormone production in these tumors is related to location [1, 2] . Increased hormone levels are often associated with fatigue, flushing, diarrhea and dyspnea [3] . Surgery is the only curative treatment and lack of cure leads to liver metastasis [2, 4] . Palliative treatment includes biological agents such as somatostatin analogues, interferon-a [2] and embolization of liver metastases.
Improved treatment strategies have contributed to better symptom control and possibly prolonged survival. Increased longevity has contributed to an emphasis on health related quality of life (HRQoL) as a secondary outcome. HRQoL is a multidimensional construct reflecting on individuals' perception of current levels of health status and well being and is not age, disease or treatment specific [5] . The majority of NET patients already have disseminated disease at the time of diagnosis due to lack of initial symptoms. Thus, most patients are already facing progressive disease at diagnosis. Assessment of HRQoL, therefore, plays a key role during clinical follow up [6, 7] . The therapeutic challenge requires a balance between evaluation of individual disability and need for palliative treatment with the risk of adverse reactions.
HRQoL has been described in numerous populations of cancer patients but only recently in patients with NET. An overview of the literature of quality of life (QOL) among NET patients showed studies rating cancer specific QOL [7, 8] , cancer specific QOL and anxiety and depression [9] , HRQoL and psychosocial function [10] and patient and staff perceptions of disease specific QOL [6] .
Methodological limitations have been identified in a number of studies. Studies included a limited number of patients, used convenience sampling, and rarely included a reference group. One study did not show statistically significant findings [11] . Results indicate that NET patients report relatively good HRQoL, in early and late stages of the disease [10] , however experienced decreased emotional and role functioning compared with general population cohorts [9, 10, 12] .
In other malignancies, overall levels of HRQoL have been reported, but group comparisons are limited by variations in time from disease onset, use of chemotherapeutics, and clinical characteristics [13, 14] . At present, the significance of HRQoL in NET patients is unclear, and only one population based HRQoL study has been published [10] . Studies comparing HRQoL between the general population and NET patients may contribute new knowledge of HRQoL and assist with development of targeted interventions. Therefore, the aim of the study was to characterize HRQoL among a nation wide sample of NET patients compared with the general Norwegian population.
Methodology

Design
A cross-sectional design using survey methodology with anonymous, self-reported questionnaires was employed. The Regional Ethics Committee, Health Region II (South) of Norway and the Norwegian Social Science Data Services approved the study.
Samples and procedures
The sample consisted of Norwegian patients diagnosed with NET and recruited from nationwide treatment centers. Cancer patients were compared to a sample of controls from the general Norwegian population [15] . NET patients were identified by NET centers in June 2007. A total of 261 NET patients were identified. Inclusions criteria were; (1) patients with tumors restricted to the GI tract; (2) ability to speak and write in Norwegian; (3) over 18 years of age; and (4) undergoing medical treatment for NET. Patients who were terminally ill, who had undergone radical surgery that may have been curative, or who suffered from cognitive or mental dysfunction were excluded from the study. Twenty-five patients did not meet inclusion criteria. The remaining 236 patients were mailed information about the study and questionnaires. Consent was assumed with return of the survey. One hundred ninety-six (83%) patients returned the questionnaire after one reminder.
General population sample
A random sample of Norwegian citizens, retrieved from the Norwegian general population database, served as controls. Citizens in the database had previously completed the SF-36 tool. The data from the Norwegian Survey of Living Conditions were collected in 2002 and are available through the Norwegian Survey Archive (NSD) [15] . NSD mailed the survey to a random sample of individuals over 18 years of age [15] . A total of 6,827 individuals (age range 15-103 years) answered the questionnaire during the period of October 2002-February 2003, which gave a response rate of 66%. Respondents within the same age range as the NET patients (23-85 years) were included (n = 5152).
Background characteristics
Sociodemographic variables such as gender, age, marital status, level of education, employment status, and income were recorded for both groups. Age was categorized into three groups: \60 years, 60-69 years, and [70 years in order to match participants to controls (see Tables 1, 2 ).
Disease specific characteristics
Disease-related variables included medical treatment and disease duration in years. Medical treatment was reported as (a) interferon, (b) somatostatin analogues (c) combination of interferon and somatostatin analougues, and/or (d) chemotherapeutics.
Assessment of HRQoL
The SF-36 was chosen as a measure of HRQoL for a number of reasons. The SF-36 was designed to be used in a population of patients with diverse health problems. The tool facilitates comparisons between groups which is important in a sample of patients with a variety of diagnoses and therapies. Furthermore, the SF-36 is more sensitive to changes in generic health status [16] while cancer specific quality of life measures reflect the disease-related functional status and symptoms [17] .
The Short Form 36 (SF-36) questionnaire measures eight dimensions of HRQoL; general health (GH), physical functioning (PF), mental health (MH), role limitations physical (RP), role limitations-emotional (RE), vitality (VT), social functioning (SF), bodily pain (BP) and change of health status during the past year. Item scores are linearly transformed into scales ranging from 0 to 100, with higher scores indicating better HRQoL [18] . The SF-36 has satisfactory psychometric properties across a wide range of populations worldwide, including Norway. The scales and items of the SF-36 have shown satisfactory reliability, validity, and responsiveness to health status [14] covering a broad spectrum of cancer patients and other patient categories [19] . In the present sample, internal consistency reliability of the SF-36 was supported with Cronbach's alpha on the eight SF-36 subscales ranging from 0.82 (Social functioning) to 0.92 (Physical functioning).
Statistical analysis
We analyzed data with SPSS version 15 and used v 2 statistics to analyze differences in background characteristics of the samples (Table 2) .
Differences in the categorical variables of gender, age, marital status, and education between groups were tested using the chi-square statistic (Table 2 ). Chi-square statistic for categorical data and Analysis of Variance (ANOVA) for continuous data were used in order to examine differences in HRQoL scores across sociodemographic and disease-related variables (Table 3) . We used post-hoc Bonferroni correction by dividing the level of significance (0.05) by the number of subscales [8] in the SF-36 resulting in an adjusted level of significance of 0.006 (Table 3) . To answer the primary research question of differences in HRQoL between NET patients and the general population, t-tests were used to analyze scores by subscales adjusting for age and gender (Table 4 ). Due to the large unequal group sizes and multiple statistical comparisons, the level of statistical significance was set at a more conservative 0.01 to evaluate differences between the patients with NET and the general population sample. In addition, effect sizes (ES) in HRQoL scores were calculated by computing the difference in mean scores divided by the pooled standard deviations. According to Cohen's classification a small effect is 0.20, a medium effect is 0.50, and large effect is 0.80 [20] (Tables 3, 4) . Table 1 shows background characteristics of the NET patients and Table 2 shows background characteristics of NET patients compared with the general population. NET patients were more likely to be older (P \ 0.001), married or living together (P \ 0.001), and less educated (P \ 0.001) than the general population sample (Table 2) . Mean age for the NET patients was 65 years (range 33-85) and differed significantly (P \ 0.001) from the general population (mean 45.6, range 15-103). Educational achievement was lower in the NET patients compared with the general population (41 vs. 17%, P \ 0.001).
Results
Sample characteristics
HRQoL, background and disease-specific characteristics of NET patients Table 3 shows the relationships between background and disease specific characteristics on dimensions of HRQoL within the NET patient sample. There were no differences between genders in HRQoL. Mean scores on physical functioning and role limitations physical were significantly lower in those above 70 years of age (P \ 0.001) compared with those who were younger. There were no significant differences between those living alone compared with those married or cohabitating. Physical functioning (P \ 0.001) was significantly higher in NET patients with more than 16 years of education compared with those with less education. HRQoL was significantly higher for those who worked full-time and part-time compared with those who did not work in the subscales of physical functioning (P \ 0.001).
The mean disease duration was 5 years (median 4 years, range 2-276 months). Thirty-nine patients had a disease duration of 2 years or less, and seven patients had disease duration of more than 20 years. There were no differences in HRQoL between groups for disease duration. Sixty-eight percent of the NET patients were treated with somatostatin analogues or interferon-a and 9% were treated with a combination of the two. Ten percent used chemotherapy and 18% reported no medication use. The medication scores on somatostatin analogues, interferon-a and chemotherapeutics did not have an affect on HRQoL. Income was significantly associated with increased physical functioning (P \ 0.001), and was not related to other HRQoL sub scores. The scores on income and medication variables differed of more than ten points on all HRQoL subscales. According to King [21] differences in mean score of ten points may be considered clinically worth-while and be of clinically important difference.
HRQoL differences between the NET patients and the general population Table 4 shows the mean scores on the subscales of the SF-36 for NET patient sample and the general population sample. Compared to the age and gender adjusted norm data, NET patients reported significantly lower scores on all SF-36 subscales (P \ 0.001) except for bodily pain. Effect sizes showed that the largest differences in HRQoL were related to general health (d = 0.84), role limitations physical (d = 0.57), and vitality (d = 0, 51). Normative values for the SF-36 have been published for the Norwegian population [19] . 
Discussion
HRQoL, background, and disease characteristics NET patients over 70 years reported decreased physical functioning and increased physical limitations when compared with their younger counterparts. This may reflect normal functional changes associated with aging. These findings are in conflict with a previous study which found no association between age and HRQoL [6] . Mols [22] reported an interaction between age and gender in women over 70 with endometrial cancer. The women reported more limitations to physical functioning and role physical when compared with men and younger women [22] . NET patients who worked full or part-time described better physical functioning and role-physical, when compared with those who were retired. Retired persons are more likely to be older which may explain these findings. An interesting finding was that there was no relationship between scores on subscales of the SF-36 and the length of time since diagnosis. These findings may be due to the tailored treatment. However, the differences within the groups of disease duration on physical functioning and social functioning were ten points and more than ten points and may be clinically relevant although not statistically significant [21] . Further studies examining disease duration and HRQoL are warranted.
HRQoL differences between NET patients and the general population
Patients with NET showed decreased HRQoL in all subscales of the SF-36 compared to age and gender matched Norwegians. These results are consistent with previous findings [23] [24] [25] [26] , however, NET patients had lower scores than a cohort of French cancer patients [20] and patients with multiple endocrine tumors [10] . This may be partially explained by the fact that the NET patients represent a group with advanced cancer and the majority of NET patients have metastatic disease (70%) [4, 27, 28] . The NET patients were diagnosed with cancer at a median of 5 years prior to the study and the median survival is reported to be 14 years [4] .
The largest differences in HRQoL were in the rolephysical limitation subscale of the SF-36. Role-physical limitation scores represent the ability to participate in activities of daily life. The NET patients had mean scores 25 points lower than the general Norwegian population. These differences may be attributed to tumor site and/or treatment that may result in a variety of distressing symptoms like fatigue, diarrhea, and depression; symptoms frequently reported by NET patients [1, 2, 8] . Finally, different therapies may also result in other debilitating side effects [29] .
The smallest difference in HRQoL scores occurred in the bodily pain subscales. Effect size was small (d = 0.17) in this subscale and suggests that there are little differences in pain between the general Norwegian population and the NET patients. In a similar study of Swedish patients with NET, there were no significant differences in bodily pain score compared with the general population [11] .
Conclusions and implications
Results of this study indicate that HRQoL is reduced in patients with neuroendocrine tumors compared to the general Norwegian population. Clinicians who have frequent contact with NET patients can assess for decreased HRQoL and intervene as specific problems arise. Clinicians can also refer patients to other social service agencies 
Strengths
This is the first study to compare HRQoL in NET patients to a random sample of the entire Norwegian population. The ability to compare scores in the NET sample to normative data helps to validate the findings in the cancer population and aids researchers and clinicians in determining the most important and amenable aspects of HRQoL in patients with neuroendocrine tumors. Additionally, the SF-36 tool discriminated between participants with disease and those of the general population [13] . Finally, the response rate to the survey in the NET population was extremely high (83%), reducing the possibility of sampling errors and increasing the reliability of the findings.
Limitations
The norm referenced data collected from the Norwegian population was collected in 2002 and it is possible that SF-36 scores may have changed in the intervening years. However, data from the NET patients were collected in 2007 so the time span of data collection was minimal between groups. Further studies are needed to determine whether results in this study can be replicated and whether the statistically significant differences in HRQoL scores are clinically relevant.
